AIMS: Receptor-type tyrosine kinases are important in cell signal transduction and proliferation. Abnormal expression of tyrosine kinases often leads to malignant transformation. c-met is a tyrosine kinase receptor and its ligand is hepatocyte growth factor (HGF). In this study, we have evaluated c-met expression in 69 invasive breast carcinomas and statistically analysed this expression with known clinicopathological prognostic parameters and patients' survival. We also studied for the first time c-met expression in association with E-cadherin and beta-catenin expression. METHODS AND RESULTS: Immunohistochemistry (ABC-HRP method) was peformed for the detection of c-met, E-cadherin and beta-catenin. c-met immunoreactivity was observed in 58% of cases and was associated with the lobular type of breast carcinomas (P = 0.012), low histological grade ductal carcinomas (P = 0.05), favourable prognostic and predictive factors such as oestrogen and progesterone receptor immunohistochemical expression and negative c-erbB-2 expression (P = 0.05, P = 0.014 and P = 0.03, respectively). c-met immunoreactivity did not correlate with lymph node status, tumour size and stage of the disease. Cox's proportional hazard regression model demonstrated that tumours with positive c-met immunoreactivity correlated significantly with favourable patients' survival (P = 0.028). When c-met staining was compared with E-cadherin and beta-catenin expression, a statistical significant correlation was established between c-met immunoreactivity and abnormal beta-catenin expression (P = 0.025) suggesting possible involvement of c-met in the downregulation of the E-cadherin-catenin complex, possibly through tyrosine phosphorylation of beta-catenin. CONCLUSION: c-met immunohistochemical expression seems to be associated with abnormal beta-catenin expression, good prognostic and predictive factors and favourable outcome in breast cancer patients.
AIMS: Receptor-type tyrosine kinases are important in cell signal transduction and proliferation. Abnormal expression of tyrosine kinases often leads to malignant transformation. c-met is a tyrosine kinase receptor and its ligand is hepatocyte growth factor (HGF). In this study, we have evaluated c-met expression in 69 invasive breast carcinomas and statistically analysed this expression with known clinicopathological prognostic parameters and patients' survival. We also studied for the first time c-met expression in association with E-cadherin and beta-catenin expression. METHODS AND RESULTS: Immunohistochemistry (ABC-HRP method) was peformed for the detection of c-met, E-cadherin and beta-catenin. c-met immunoreactivity was observed in 58% of cases and was associated with the lobular type of breast carcinomas (P = 0.012), low histological grade ductal carcinomas (P = 0.05), favourable prognostic and predictive factors such as oestrogen and progesterone receptor immunohistochemical expression and negative c-erbB-2 expression (P = 0.05, P = 0.014 and P = 0.03, respectively). c-met immunoreactivity did not correlate with lymph node status, tumour size and stage of the disease. Cox's proportional hazard regression model demonstrated that tumours with positive c-met immunoreactivity correlated significantly with favourable patients' survival (P = 0.028). When c-met staining was compared with E-cadherin and beta-catenin expression, a statistical significant correlation was established between c-met immunoreactivity and abnormal beta-catenin expression (P = 0.025) suggesting possible involvement of c-met in the downregulation of the E-cadherin-catenin complex, possibly through tyrosine phosphorylation of beta-catenin. CONCLUSION:c-met immunohistochemical expression seems to be associated with abnormal beta-catenin expression, good prognostic and predictive factors and favourable outcome in breast cancerpatients.
Authors: Chuanhui Xu; Wouter Plattel; Anke van den Berg; Nele Rüther; Xin Huang; Miao Wang; Debora de Jong; Hans Vos; Gustaaf van Imhoff; Andreas Viardot; Peter Möller; Sibrand Poppema; Arjan Diepstra; Lydia Visser Journal: Haematologica Date: 2011-12-16 Impact factor: 9.941
Authors: Andrey I Khramtsov; Galina F Khramtsova; Maria Tretiakova; Dezheng Huo; Olufunmilayo I Olopade; Kathleen H Goss Journal: Am J Pathol Date: 2010-04-15 Impact factor: 4.307
Authors: Lan Zhou; Naili An; Rex C Haydon; Qixin Zhou; Hongwei Cheng; Ying Peng; Wei Jiang; Hue H Luu; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Benjamin Breyer; Tong-Chuan He Journal: Cancer Lett Date: 2003-04-25 Impact factor: 8.679
Authors: Silvie Foldynová-Trantírková; Petra Sekyrová; Katerina Tmejová; Eva Brumovská; Ondrej Bernatík; Wulf Blankenfeldt; Pavel Krejcí; Alois Kozubík; Tomás Dolezal; Lukás Trantírek; Vítezslav Bryja Journal: Breast Cancer Res Date: 2010-05-27 Impact factor: 6.466